ResMed Files Annual 10-K Report as Company Approaches Dividend Payment
The medical device maker submitted its annual financial disclosure to the SEC, with a quarterly dividend and earnings report scheduled for the coming months.
Annual Filing Submitted
ResMed Inc. (RMD) filed its annual report on Form 10-K with the Securities and Exchange Commission on August 13, according to SEC EDGAR filings. The San Diego-based medical device manufacturer, which specializes in sleep apnea treatment and respiratory care equipment, submitted the comprehensive annual disclosure as required for publicly traded companies.
The company, with a market capitalization of approximately $33 billion, closed at $226 per share in its most recent trading session.
Upcoming Corporate Actions
ResMed shareholders have several key dates to monitor in the coming months. According to MarginX data, the company will pay a cash dividend of $0.66 per share on August 20, 2026, providing income to eligible investors.
The company is expected to report its first-quarter fiscal 2027 results on October 29, 2026, which will offer investors updated insight into the medical device maker's operational performance and market conditions in the respiratory care sector.
Insider Activity Noted
Recent regulatory filings show insider transactions by Michael J. Farrell, who exercised options totaling 9,982 shares across two separate transactions, according to MarginX data. Farrell subsequently sold 4,991 shares. Such option exercises and sales are routine corporate actions that executives often undertake for tax planning, diversification, or other personal financial management purposes.
Broader Market Context
The filing comes as market participants also await Federal Reserve policy decisions, with FOMC meetings scheduled for September 16 and October 28, 2026, according to MarginX data. The September meeting will include updated economic projections, potentially influencing sentiment across healthcare and medical device sectors.
The 10-K filing provides investors and analysts with detailed information about ResMed's financial condition, business operations, risk factors, and management discussion for the completed fiscal year.
This article was generated by MarginX from public news on 2026-08-13. It is not investment advice.